November 30, 2007 - New Data on Targeted Therapy with Chemo/Radiotherapy as Multimodality Management for Various Malignancies Presented at the 2007 ASTRO Meeting
You must log in to view detailed articles. Enter your e-mail address and password in the box to the right, or you can register here.
This article has PDF attachments. Log in to view them.
New Data on Targeted Therapy with Chemo/Radiotherapy as Multimodality Management for Various Malignancies Presented at the 2007 ASTRO Meeting
Editorial Insights
John Horton, MB, ChB, FACP
Editor, Cancer Control Journal
Emeritus Professor of Medicine and Oncology
H. Lee Moffitt Cancer Center & Research Institute
University of South Florida College of Medicine
This issue of The Podium Report is based upon selected data and discussions from scientific presentations at the 2007 49th Annual Meeting of the American Society for Therapeutic Radiology and Oncology in Los Angeles, October 28-November 1. ASTRO's Annual Meeting is the premier scientific event in radiation oncology and is designed to address the educational needs of radiation oncologists, physicists, biologists, nurses and other healthcare professionals involved in the field of radiation oncology, as well as oncologists working in related specialties.
In this issue we focus on findings of research presented at the meeting on data for the employment of targeted therapy with monoclonal antibodies in conjunction with therapeutic radiology. Agents such as cetuximab, trastuzumab, bevacizumab and panitumumab are emerging as important adjuncts to chemotherapy and radiation therapy for a variety of malignancies. In recent years, improvements in the understanding of the molecular etiology of cancer have enabled the development of novel targeted therapies, and there has been special interest in pursuing targeted therapy of cancers via inhibition of the epidermal growth factor receptor (EGFR).1
We report on data from a number of important trials presented at the ASTRO meeting. A number of trials of cetuximab plus chemoradiotherapy in head and neck cancer and in non-small cell lung cancer (NSCLC) received attention. Oral presentations were made on data from a trial of surgery followed by chemoradiation plus cetuximab for high-risk squamous cell carcinoma of the head and neck (SCCHC) and on cetuximab in combination with chemoradiation for NSCLC. In addition, there were oral reports on bevacizumab in pancreatic cancer and high-grade gliomas. There also were posters on trastuzumab in breast cancer and one with early data on panitumumab in aerodigestive tract cancers.
Despite advances, progress is needed in the knowledge of treatment of malignancies with the combination of targeted therapy and chemoradiation. Optimal combinations of these therapeutic modalities are still to be sought. Data presented at meetings such as ASTRO 2007 can make an important contributions to progress in management and to improvements in patient outcomes. With the objective of bringing information on new data to solving the problems of treatment we report on selected presentations from this conference. In our coverage, we have placed emphasis on trials that we believe will have a significant impact on the treatment strategies as we move into 2008.
The University of South Florida College of Medicine and H. Lee Moffitt Cancer Center & Research Institute wish to acknowledge the support of ImClone Systems, Inc., which has provided an educational grant for this CME activity.
Disclosure of faculty and commercial support relationships is required of the contributors to this CME activity. The following relationships have been disclosed:
John Horton, MB, ChB, FACP, Editor, Medical reviewer – Nothing to disclose.
Maria B. Uravich, ELS, USF Health CME Specialist – Nothing to disclose.
Donna Dickinson, RN – Scientific News International, Inc. – Nothing to disclose.
Credit Hour Designation/Self-Test
Target Audience:
This activity is intended for medical oncologists and radiation oncologists.
Learning Objectives:
- Describe evolving data on the treatment of malignancies employing targeted therapy in multimodality approaches with chemoradiation
- Develop strategies for adapting these data to daily practice
- Anticipate future directions in the management of various malignancies using these approaches
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the University of South Florida College of Medicine, H. Lee Moffitt Cancer Center & Research Institute, and Scientific News International, Inc. The University of South Florida College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
The University of South Florida College of Medicine designates this educational activity for a maximum of 1 AMA PRA Category 1 CreditTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Release date: November 28, 2007
Expiration date: November 30, 2008
Estimated time to complete this activity: 1 hour
Please use the links above to access the full article and its related CME self-test.
Privacy Policy
The University of South Florida Office of Continuing Professional Development (OCPD) has created a privacy policy to demonstrate our commitment to guarding the privacy of our clients. The following statements disclose our practices on gathering and disseminating information for this web site. The OCPD has security measures in place to protect the loss, misuse, and alteration of the information under our control. The OCPD does not share or sell any individual's contact information, financial information, or unique identifiers to any commercial supporter, advertiser, or third party without the specific permission of the individual. If you have any questions about this privacy policy, please contact Beverly Hughes, Director of Continuing Professional Development, USF OCPD, at bhughes@health.usf.edu.
You must log in to view detailed articles. Enter your e-mail address and password in the box to the right, or you can register here.
This article has PDF attachments. Log in to view them.